Oryzon Genomics S.A. (BME:ORY)
Spain
· Delayed Price · Currency is EUR 2.790
-0.022 (-0.78%)
Apr 28, 2026, 5:35 PM CET
Oryzon Genomics Employees
Oryzon Genomics had 46 employees as of December 31, 2025. The number of employees decreased by 1 or -2.13% compared to the previous year.
Employees
46
Change (1Y)
-1
Growth (1Y)
-2.13%
Revenue / Employee
€237,705
Profits / Employee
€56,641
Market Cap
217.97M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| Grifols | 25,258 |
| Laboratorios Farmaceuticos Rovi | 2,045 |
| Almirall | 2,108 |
| Pharma Mar | 505 |
| Clínica Baviera | 1,861 |
| Prim, S.A. | 984 |
| Atrys Health | 1,985 |
| Laboratorio Reig Jofre | 1,512 |
Oryzon Genomics News
- 2 months ago - ORYZON Reports Financial Results and Corporate Update for Quarter Ended December 31st, 2025 - GlobeNewsWire
- 4 months ago - ORYZON Expands Global Patent Protection for Iadademstat with Grant Decision in Japan Covering Combinations with PD-1/PD-L1 Inhibitors - GlobeNewsWire
- 4 months ago - ORYZON Announces the Voting Results of December 2025 Extraordinary General Shareholders' Meeting - GlobeNewsWire
- 6 months ago - ORYZON Reports Financial Results and Corporate Update for Quarter Ended September 30, 2025 - GlobeNewsWire
- 6 months ago - ORYZON Announces First‑Patient‑In (FPI) in RESTORE Phase Ib Trial of Iadademstat in Sickle Cell Disease - GlobeNewsWire
- 6 months ago - ORYZON to Participate in Upcoming Events in November - GlobeNewsWire
- 6 months ago - ORYZON Receives Feedback From the FDA in Response to the Submitted Phase III Protocol in Borderline Personality Disorder - GlobeNewsWire
- 7 months ago - ORYZON Strengthens Patent Portfolio for iadademstat with European Grant Decision Covering Combinations with PD1/PD-L1 Inhibitors - GlobeNewsWire